Ovascience, Inc. (OVAS): Michelle Dipp , CEO of Ovascience, Inc. purchased 20,000 shares on May 11, 2016. The Insider buying transaction was reported by the company on May 13, 2016 to the Securities and Exchange Commission. The shares were purchased at $7.64 per share for a total value of $152,800.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 13, 2016, Richard Aldrich (director) purchased 20,000 shares at $7.64 per share price.On May 12, 2016, Paul W.d. Chapman (COO) purchased 3,100 shares at $7.37 per share price.Also, On May 12, 2016, Michelle Dipp (CEO) purchased 19,900 shares at $7.72 per share price.On Oct 7, 2015, Jeffrey E Young (CFO) purchased 3,450 shares at $10.70 per share price.
OvaScience Inc: On Tuesday, May 10, 2016 heightened volatility was witnessed in OvaScience Inc which led to swings in the share price. The shares opened for trading at $7.37 and hit $8 on the upside , eventually ending the session at $7.9, with a gain of 11.74% or 0.83 points. The heightened volatility saw the trading volume jump to 7,24,365 shares. The 52-week high of the share price is $39.29 and the company has a market cap of $216 M . The 52-week low of the share price is at $4.53.
OvaScience Inc. is a global fertility company. The Company is focused on the discovery development and commercialization of new fertility treatments based on egg precursor or EggPC cells which are immature egg cells found in the protective outer layer of a woman’s own ovaries. With the Company’s AUGMENT treatment energy-producing mitochondria from a patient’s own EggPC cells are added to the patient’s mature eggs during the In vitro fertilization (IVF) process to supplement the existing mitochondria. Its OvaPrime treatment is designed to replenish a woman’s egg reserve by transferring a patient’s EggPC cells from the protective ovarian lining back into the patient’s own ovaries where they may mature into fertilizable eggs during the IVF process. The OvaTure treatment seeks to mature a woman’s own EggPC cells into eggs outside her body. The OvaXon is a joint venture with Intrexon Corporation to create new applications to prevent inherited diseases for human and animal health.